{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:01Z","timestamp":1707525181281},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,29]]},"DOI":"10.7759\/cureus.42652","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T15:29:01Z","timestamp":1690644541000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Post-COVID-19 Rhino-Cerebral Mucormycosis in an Immunocompromised Patient"],"prefix":"10.7759","author":[{"given":"Labeeba","family":"Faria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasnova","family":"Mahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Abdul","family":"Qader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosaddeque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad A","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2011.04.048","article-title":"Management and outcomes of three cases of rhinocerebral mucormycosis","volume":"112","author":"Viterbo S","year":"2011","unstructured":"Viterbo S, Fasolis M, Garzino-Demo P, et al.. Management and outcomes of three cases of rhinocerebral mucormycosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011, 112:e69-74. 10.1016\/j.tripleo.2011.04.048","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref2","article-title":"[Zygomycetes and zygomycosis in the new era of antifungal therapies]","volume":"20","author":"Torres-Narbona M","year":"2007","unstructured":"Torres-Narbona M, Guinea J, Mu\u00f1oz P, Bouza E. [Zygomycetes and zygomycosis in the new era of antifungal therapies]. Rev Esp Quimioter. 2007, 20:375-86.","journal-title":"Rev Esp Quimioter"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ccd.ccd_558_17","article-title":"Mucormycosis in a diabetic patient: a case report with an insight into its pathophysiology","volume":"8","author":"Afroze SN","year":"2017","unstructured":"Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a diabetic patient: a case report with an insight into its pathophysiology. Contemp Clin Dent. 2017, 8:662-6. 10.4103\/ccd.ccd_558_17","journal-title":"Contemp Clin Dent"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2018.10.005","article-title":"Treatment of cerebral mucormycosis with drug therapy alone: a case report","volume":"23","author":"Elzein F","year":"2019","unstructured":"Elzein F, Kalam K, Mohammed N, Elzein A, Alotaibi FZ, Khan M, Albadani A. Treatment of cerebral mucormycosis with drug therapy alone: a case report. Med Mycol Case Rep. 2019, 23:4-7. 10.1016\/j.mmcr.2018.10.005","journal-title":"Med Mycol Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir865","article-title":"Pathogenesis of mucormycosis","volume":"54 Suppl 1","author":"Ibrahim AS","year":"2012","unstructured":"Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012, 54 Suppl 1:S16-22. 10.1093\/cid\/cir865","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1086\/427690","article-title":"Serious infections in elderly patients with diabetes mellitus","volume":"40","author":"Rajagopalan S","year":"2005","unstructured":"Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis. 2005, 40:990-6. 10.1086\/427690","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2016.11.130","article-title":"Affinity of mucormycosis for basal ganglia in intravenous drug users: case illustration and review of literature","volume":"98","author":"Hazama A","year":"2017","unstructured":"Hazama A, Galgano M, Fullmer J, Hall W, Chin L. Affinity of mucormycosis for basal ganglia in intravenous drug users: case illustration and review of literature. World Neurosurg. 2017, 98:872.e1-3. 10.1016\/j.wneu.2016.11.130","journal-title":"World Neurosurg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10726","article-title":"Rhino-orbital mucormycosis associated with COVID-19","volume":"12","author":"Mehta S","year":"2020","unstructured":"Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020, 12:e10726. 10.7759\/cureus.10726","journal-title":"Cureus"},{"key":"ref9","article-title":"Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment","author":"Marx RE","year":"2003","unstructured":"Marx RE, Stern D. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. Quintessence Publishing, Chicago; 2003."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/joms.2001.23407","article-title":"A fatal outcome from rhinocerebral mucormycosis after dental extractions: a case report","volume":"59","author":"Kim J","year":"2001","unstructured":"Kim J, Fortson JK, Cook HE. A fatal outcome from rhinocerebral mucormycosis after dental extractions: a case report. J Oral Maxillofac Surg. 2001, 59:693-7. 10.1053\/joms.2001.23407","journal-title":"J Oral Maxillofac Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01561-x","article-title":"A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis","volume":"49","author":"Pasero D","year":"2021","unstructured":"Pasero D, Sanna S, Liperi C, et al.. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2021, 49:1055-60. 10.1007\/s15010-020-01561-x","journal-title":"Infection"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-241663","article-title":"COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?","volume":"14","author":"Revannavar SM","year":"2021","unstructured":"Revannavar SM, P S S, Samaga L, V K V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?. BMJ Case Rep. 2021, 14:10.1136\/bcr-2021-241663","journal-title":"BMJ Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_3774_20","article-title":"Mucor in a viral land: a tale of two pathogens","volume":"69","author":"Sen M","year":"2021","unstructured":"Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021, 69:244-52. 10.4103\/ijo.IJO_3774_20","journal-title":"Indian J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(05)80041-4","article-title":"Survival factors in rhino-orbital-cerebral mucormycosis","volume":"39","author":"Yohai RA","year":"1994","unstructured":"Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. SurvOphthalmol. 1994, 39:3-22. 10.1016\/s0039-6257(05)80041-4","journal-title":"SurvOphthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden MM","year":"2005","unstructured":"Roden MM, Zaoutis TE, Buchanan WL, et al.. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005, 41:634-53. 10.1086\/432579","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001653691","article-title":"Improved outcome of zygomycosis in patients with hematological diseases?","volume":"45","author":"Gleissner B","year":"2004","unstructured":"Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma. 2004, 45:1351-60. 10.1080\/10428190310001653691","journal-title":"Leuk Lymphoma"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot F","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, et al.. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017, 102:433-44. 10.3324\/haematol.2016.152900","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/133623-a-case-of-post-covid-19-rhino-cerebral-mucormycosis-in-an-immunocompromised-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:02Z","timestamp":1707509042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/133623-a-case-of-post-covid-19-rhino-cerebral-mucormycosis-in-an-immunocompromised-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.42652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,29]]}}}